Neve KA - Search Results

1

Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands.

Watts VJ, Lawler CP, Knoerzer T, Mayleben MA, Neve KA, Nichols DE, Mailman RB. Watts VJ, et al. Among authors: neve ka. Eur J Pharmacol. 1993 Aug 3;239(1-3):271-3. doi: 10.1016/0014-2999(93)91012-c. Eur J Pharmacol. 1993. PMID: 8223910

2

Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine.

Janowsky A, Neve KA, Kinzie JM, Taylor B, de Paulis T, Belknap JK. Janowsky A, et al. Among authors: neve ka. J Pharmacol Exp Ther. 1992 Jun;261(3):1282-90. J Pharmacol Exp Ther. 1992. PMID: 1534844

3

LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors.

Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB. Watts VJ, et al. Among authors: neve ka. Psychopharmacology (Berl). 1995 Apr;118(4):401-9. doi: 10.1007/BF02245940. Psychopharmacology (Berl). 1995. PMID: 7568626

4

Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors.

Watts VJ, Neve KA. Watts VJ, et al. Among authors: neve ka. Mol Pharmacol. 1996 Oct;50(4):966-76. Mol Pharmacol. 1996. PMID: 8863843

5

Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors.

Watts VJ, Neve KA. Watts VJ, et al. Among authors: neve ka. Mol Pharmacol. 1997 Aug;52(2):181-6. doi: 10.1124/mol.52.2.181. Mol Pharmacol. 1997. PMID: 9271339

6

Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells.

Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, Neve KA. Watts VJ, et al. Among authors: neve rl, neve ka. J Neurosci. 1998 Nov 1;18(21):8692-9. doi: 10.1523/JNEUROSCI.18-21-08692.1998. J Neurosci. 1998. PMID: 9786976 Free PMC article.

7

Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors.

Watts VJ, Vu MN, Wiens BL, Jovanovic V, Van Tol HH, Neve KA. Watts VJ, et al. Among authors: neve ka. Psychopharmacology (Berl). 1999 Jan;141(1):83-92. doi: 10.1007/s002130050810. Psychopharmacology (Berl). 1999. PMID: 9952069

8

Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity.

Schutzer WE, Watts VJ, Chapman J, Cumbay MG, Neve KA, Neve RL, Mader SL. Schutzer WE, et al. Among authors: neve rl, neve ka. Clin Exp Pharmacol Physiol. 2000 Jan-Feb;27(1-2):9-13. doi: 10.1046/j.1440-1681.2000.03210.x. Clin Exp Pharmacol Physiol. 2000. PMID: 10696522

9

Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor.

Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, DuRand CJ, Teeter MM. Neve KA, et al. Mol Pharmacol. 2001 Aug;60(2):373-81. doi: 10.1124/mol.60.2.373. Mol Pharmacol. 2001. PMID: 11455025

10

Dopamine D2 receptor-induced heterologous sensitization of adenylyl cyclase requires Galphas: characterization of Galphas-insensitive mutants of adenylyl cyclase V.

Watts VJ, Taussig R, Neve RL, Neve KA. Watts VJ, et al. Among authors: neve rl, neve ka. Mol Pharmacol. 2001 Dec;60(6):1168-72. doi: 10.1124/mol.60.6.1168. Mol Pharmacol. 2001. PMID: 11723222

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters